RTX-GRT7039

DRUG4 trials

Sponsors

Gruenenthal GmbH, Grünenthal GmbH

Conditions

Moderate to severe pain associated with Osteoarthritis of the kneeOsteoarthritis

Phase 3

Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

CompletedNCT05248386

Grünenthal GmbHOsteoarthritis

Start: 2022-08-26End: 2024-11-18Updated: 2026-03-18

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

CompletedNCT05377489

Grünenthal GmbHOsteoarthritis

Start: 2022-09-15End: 2025-05-15Updated: 2026-03-12

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

CompletedNCT05449132

Grünenthal GmbHOsteoarthritis

Start: 2022-09-26End: 2024-08-15Updated: 2026-03-18

A single-arm, open-label, Phase III trial to evaluate the safety and tolerability of intra-articular injections of RTX-GRT7039 in subjects with moderate to severe pain associated with osteoarthritis of the knee.

CompletedCTIS2024-515709-24-00

Gruenenthal GmbHModerate to severe pain associated with Osteoarthritis of the knee

Start: 2022-07-26End: 2025-03-28Target: 511Updated: 2025-02-28